Reference
·Supporting source
Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)
~THB 6,000-9,000 per sample (COGS)
Cost-of-goods on a representative 50-gene oncology NGS panel ran at THB 6,000-9,000 per sample in 2026, down from THB 11,000-15,000 in 2022, as Illumina, MGI, and Pacific Biosciences competition matured and Thai-anchored lab volume scaled. The cost figure covers reagents, library preparation, sequencer amortisation, bioinformatics, and clinical reporting. Pharmacogenomic panels (CYP-family plus HLA-B*1502) sit lower at THB 1,800-3,500 per sample on TaqMan or focused-array platforms. Liquid-biopsy ctDNA monitoring runs THB 12,000-22,000 per draw given the deeper sequencing requirement. Gross margin under NHSO reimbursement sits 35-50%; private-pay Thai and medical-tourism gross margin runs 55-70%.
Figure in context
Cost-of-goods on a representative 50-gene oncology NGS panel ran at THB 6,000-9,000 per sample in 2026, down from THB 11,000-15,000 in 2022, as Illumina, MGI, and Pacific Biosciences competition matured and Thai-anchored lab volume scaled. The cost figure covers reagents, library preparation, sequencer amortisation, bioinformatics, and clinical reporting. Pharmacogenomic panels (CYP-family plus HLA-B*1502) sit lower at THB 1,800-3,500 per sample on TaqMan or focused-array platforms. Liquid-biopsy ctDNA monitoring runs THB 12,000-22,000 per draw given the deeper sequencing requirement. Gross margin under NHSO reimbursement sits 35-50%; private-pay Thai and medical-tourism gross margin runs 55-70%.
Cost-of-goods on a representative 50-gene oncology NGS panel ran at THB 6,000-9,000 per sample in 2026, down from THB 11,000-15,000 in 2022, as Illumina, MGI, and Pacific Biosciences competition matured and Thai-anchored lab volume scaled. The cost figure covers reagents, library preparation, sequencer amortisation, bioinformatics, and clinical reporting. Pharmacogenomic panels (CYP-family plus HLA-B*1502) sit lower at THB 1,800-3,500 per sample on TaqMan or focused-array platforms. Liquid-biopsy ctDNA monitoring runs THB 12,000-22,000 per draw given the deeper sequencing requirement. Gross margin under NHSO reimbursement sits 35-50%; private-pay Thai and medical-tourism gross margin runs 55-70%.
Time scope
FY2026
Source basis
Supporting source
Interpretation notes
What this tells you
Cost-of-goods on a representative 50-gene oncology NGS panel ran at THB 6,000-9,000 per sample in 2026, down from THB 11,000-15,000 in 2022, as Illumina, MGI, and Pacific Biosciences competition matured and Thai-anchored lab volume scaled. The cost figure covers reagents, library preparation, sequencer amortisation, bioinformatics, and clinical reporting. Pharmacogenomic panels (CYP-family plus HLA-B*1502) sit lower at THB 1,800-3,500 per sample on TaqMan or focused-array platforms. Liquid-biopsy ctDNA monitoring runs THB 12,000-22,000 per draw given the deeper sequencing requirement. Gross margin under NHSO reimbursement sits 35-50%; private-pay Thai and medical-tourism gross margin runs 55-70%.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand Precision Medicine Market Size — 2027 Projection
NHSO NLEM planning documents, Thai FDA NGS CDx framework draft, lab operator filings, hospital programme disclosures, Insight Research triangulation
Genome Thailand Cohort Size — 2026 Milestone
DMSc Genome Thailand programme documents, NIH-DMSc, MoPH
NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027
NHSO National List of Essential Medicines planning documents, NHSO public consultations, hospital partner disclosures
Thailand Hospital-Integrated Personalised Cancer Package ASP
BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation
Thailand Precision Medicine Test-Type Mix — 2026 Estimate
Lab operator filings, hospital programme disclosures, NHSO planning documents, Insight Research triangulation
Thailand Precision Medicine Operator Concentration — Top 6 Share
Operator disclosures, hospital programme websites, lab filings, Insight Research triangulation
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.